Financial Impact of Hidradenitis Suppurativa in Spain - Top-Institutions - MDSpire

Financial Impact of Hidradenitis Suppurativa in Spain

  • By

  • Eva Vilarrasa

  • Joaquín Borrás-Blasco

  • Silvia Lobo-Benito

  • Marta Loro-Pérez

  • Marta Garcia Núñez-García

  • Juan Oliva-Moreno

  • David Palacios-Martínez

  • Félix Rubial-Bernárdez

  • Yoana Ivanova-Markova

  • Mathilde Daheron

  • Javier Bellas

  • Antonio Martorell

  • February 22, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #2

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Inflammatory Diseases
    • Health Economics

  • #3

    King's College London
    King's College London

    London, N/A

    Key Differentiators

    • Dermatology
    • Clinical Epidemiology
    • Health Services Research

  • #4

    Hospital Universitario Ramón y Cajal
    Hospital Universitario Ramón y Cajal

    Madrid, N/A

    Key Differentiators

    • Dermatology
    • Clinical Research
    • Health Economics

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Dermatology
    • Immunology
    • Health Outcomes Research

Original Source(s)

Financial Impact of Hidradenitis Suppurativa in Spain

  • by Eva Vilarrasa, Joaquín Borrás-Blasco, Silvia Lobo-Benito, Marta Loro-Pérez, Marta Garcia Núñez-García, Juan Oliva-Moreno, David Palacios-Martínez, Félix Rubial-Bernárdez, Yoana Ivanova-Markova, Mathilde Daheron, Javier Bellas, Antonio Martorell

  • February 22, 2026

Related Content

Top 10 Evidence-Based Essentials in Dermatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.